56.40 -0.17 (-0.30%)
After hours: 7:51PM EST
|Bid||56.40 x 1400|
|Ask||56.79 x 800|
|Day's Range||56.13 - 58.44|
|52 Week Range||29.34 - 74.00|
|Beta (5Y Monthly)||3.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2020 - Feb 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||77.50|
The saga over who owns the valuable patents that cover CRISPR/Cas9 gene editing took a new turn this week with a court decision that goes against the Broad Institute of Harvard and MIT and two local startups.
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 06, 2020 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
If you look for mutual funds to invest in, 2019 was a blast. The S&P; 500's 2019 gain of 31.49% was the broad market's best since 2013's 32.39%.
Shares of CRISPR gene-editing companies tumbled Monday after the Chinese scientist who created the world's first genetically edited babies was sentenced to three years behind bars.
Crispr Therapeutics is a top pick heading into 2020, an analyst said Friday, noting the biotech's CRISPR gene-editing drugs could soon boost shares. Crispr stock topped a profit-taking zone.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 27, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.
Swing trading usually focuses on small gains but can see outsized gains with good news. CRISPR Therapeutics stock gives a recent example.
It's looking like cannabis stocks just might have bottomed out, and it has been a long time coming. In this week's episode of "Moneyline," Matt McCall wants investors to know that if they have a long-term perspective, the fundamentals really do matter. That's why he's still confident in pot despite its serious shellacking.Well, why's that? Just this week, the U.S. House of Representative's Judiciary Committee approved a bill that legalizes marijuana at the federal level. Many analysts say it's likely the bill will pass the Democrat-controlled House, but it faces a tougher battle in the Senate. But that doesn't matter. The existence of the bill itself is still a good sign for cannabis investors. McCall is declaring 2020 the year of cannabis -- politicians just need to wake up. He argues such legislation would essentially solve the vaping crisis and clear up issues with black-market marijuana.So how can investors play this week's good news? Start with U.S. cannabis companies. Take a look at Charlotte's Web (OTCMKTS:CWBHF) and Acreage Holdings (OTCMKTS:ACRGF). Those companies, along with a few others, are reporting annualized revenue between $100 million and $200 million. McCall says now is a perfect opportunity to build on existing positions in these names or add new ones, as these stocks have bright futures ahead. And while he's still a fan of the big Canadian names, there are better opportunities to get lit right now.InvestorPlace - Stock Market News, Stock Advice & Trading Tips McCall's PodcastThere's another emerging trend that McCall is big on: biotech stocks. There's one name in particular, Crispr Therapeutics (NASDAQ:CRSP), that's making big waves. CRSP stock is up an amazing 120% year-to-date -- and McCall identified this name earlier in 2019 as part of his Early Stage Investing portfolio for its potential in gene editing. * 7 Companies Using Artificial Intelligence to Outperform the Market This week's news easily justified CRSP's place in that portfolio. On Nov. 19, Crispr announced that patients receiving its CTX001 gene-editing therapy were experiencing significant benefits. This therapy is specifically designed for patients with severe blood disorders, and works by singling out and editing affected cells. One patient living with a form of beta thalassemia had been dependent on blood transfusions, receiving as many as 16 a year. After nine months with CTX001, that patient is now considered transfusion independent.McCall is particularly interested in the treatment's use in patients with sickle cell disease, a blood disorder that causes severe pain. And based on his recent travels to Lisbon, Portugal, healthcare will soon evolve to cure these diseases. In the future, he believes they'll even be cured at the embryonic level.So what else did he learn in Portugal? Tune in to "Moneyline" for more on his travels and the future of healthcare as it relates to artificial intelligence.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Companies Using Artificial Intelligence to Outperform the Market * 7 Earnings Reports to Watch Next Week * 6 Retail Stocks Dropping Hard Ahead of Black Friday The post Consider Adding New Positions in U.S. Cannabis Stocks appeared first on InvestorPlace.
Axsome Therapeutics is on a tear this year - with shares skyrocketing over 3,000%. This comes as the biotech company's migraine drug posted successful results in a late-stage study. Yahoo Finance's Anjalee Khemlani joins Seana Smith on The Ticker to discuss.